SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending due to a major deal with OpenAI, involving a significant purchase of AMD's GPUs and a potential equity stake, which has sent the stock soaring and sparked discussion about AMD's role in the AI landscape. The community is analyzing the deal's long-term implications, debating whether it's a game-changer that positions AMD as a strong competitor to NVDA, or if it's an overhyped event with concerns around dilution and profitability. Many are also weighing the potential for a pullback after the surge.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

The crypto community is rallying around $WAGMI, fueled by the optimistic ethos of "We're All Gonna Make It" and potential upcoming exchange listings. Many see it as more than just a meme token, but a community-driven movement, particularly within the Solana ecosystem and the broader meme coin landscape. Discussions also highlight its association with other tokens like $DOGE, $PEPE, $UPDOG, and $BROKE.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE is trending as the community discusses its potential alongside other meme coins like HONK, with some suggesting it's time to accumulate during dips. There's also speculation about PEPE's future performance in comparison to other coins, while some traders are exploring new Solana-based meme coins as potential alternatives. The conversation also includes UpDog.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin ($APP) is trending downwards following reports of an SEC probe into the company's data collection practices, sparking debate about its growth and valuation. While some investors see this as a buying opportunity, others are concerned about potential regulatory challenges and draw comparisons to past market setups. Community discussions revolve around the probe's legitimacy, the company's fundamentals, and potential impact on its future performance.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending due to strong bullish sentiment around its pivot towards AI infrastructure and data centers, with investors drawing comparisons to high-growth tech stocks like Nvidia. The community is actively discussing the potential for IREN to secure major deals with hyperscalers and the impact of its existing Bitcoin mining operations. Bullish investors believe the stock is undervalued given its potential in the AI sector, while others are wary of overbought conditions and potential dilution.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community rallies around the nostalgia of the Rage Guy meme and early internet culture. Community members express excitement and encourage others to join, emphasizing the strength of the $RAGE community. The coin is presented as more than just a ticker, but a revival of the raw, unfiltered energy of the internet's past.

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

SPRB is trending due to a significant surge following FDA breakthrough therapy designation, sparking excitement among holders. The community is actively discussing the stock's potential for further gains and comparing it to other high-flying runners, while also speculating about possible dilutions. Some traders are also closely monitoring other stocks in the same sector, hoping they will follow a similar trajectory.

Clown Pepe, also known as Honk, its original name pepoclown, is a depiction of Pepe the Frog wearing a rainbow wig and red clown nose.  $HONK, the meme coin with 0 taxes, draws its inspiration from Clown Pepe, also known as Honk Honk or Honkler. This whimsical character, originally named pepoclown, depicts Pepe the Frog donning a rainbow wig and a red clown nose. Honkler is often associated with corny or cringeworthy jokes and the emojis, symbolizing the phrase "Clown World." Embracing the chaotic and absurd nature of meme culture, $HONK aims to bring humor, memes and vibes to the space.

Pepoclown

$HONK, a 4chan-inspired meme coin featuring Honkler the clown, is gaining traction as community members highlight its strong narrative and potential for significant growth within the Ethereum meme ecosystem.  With comparisons being drawn to $PEPE and endorsements of 'clown world' culture, the community rallies around $HONK as a symbol of humor and resilience in the crypto space. Discussions revolve around its potential as a low-cap gem and a key player in the ongoing 'frog season'.

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

$4CHAN is trending as community members rally around its potential as the 'Bitcoin of memecoins,' highlighting its organic origins and strong community. Bullish sentiment focuses on the possibility of significant gains and 'dropping zeros,' while also associating it with other popular meme tokens like $PEPE, $HONK, and $TRUMP. Some users are pointing to the charts, seeing a potential breakout.

HIVE Digital Technologies Ltd. engages in building a bridge between the digital currency and blockchain sector and traditional capital markets. It operates data centers for computing and mining cryptocurrencies, including Bitcoin and other coins. The firm owns and operates green energy-powered data center facilities in Canada, Sweden, and Iceland. Its project includes Iceland Cryptocurrency Mining. HIVE Digital Technologies was founded on June 24, 1987 and is headquartered in San Antonio, TX.

HIVE Digital Technologies Ltd.

HIVE Digital Technologies Ltd

HIVE Digital Technologies is trending as community members discuss the company's potential to mirror the success of other data center and crypto mining firms like $IREN, with some highlighting its impressive Bitcoin production numbers and potential for significant growth. Chatter suggests HIVE is undervalued, especially given its expansion into High-Performance Computing (HPC) and AI, and its strategic partnerships. Investors are closely watching for a breakout above key resistance levels, anticipating a substantial price increase.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail chatter around Crinetics Pharmaceuticals picked up on Thursday after the U.S. Food and Drug Administration approved its lead therapy Palsonify (paltusotine) for adults with acromegaly.<a href="https://stocktwits.com/symbol/CRNX">Crinetics’ stock</a> closed Thursday up 2.02% at $35.89 and added another 0.8% in after-hours trading.The once-daily oral treatment is the first of its kind to be cleared in the U.S. for patients who do not respond to surgery or are unable to undergo surgery. The FDA decision was supported by two pivotal Phase 3 trials, PATHFNDR-1 and PATHFNDR-2, in which Palsonify was well-tolerated, provided rapid and durable biochemical control, and reduced symptom burden. Patients reported improvements in headaches, fatigue, joint pain and swelling.Crinetics released&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/crinetics-pharma-s-oral-drug-shows-lasting-relief-for-acromegaly-patients-in-latest-study-retail-buzz-builds/ch8B1oBR5Nq">long-term data in July</a> from the same studies, showing that patients who switched from monthly injections to Palsonify were able to maintain steady hormone levels for nearly two years.&nbsp;Symptom flares fell significantly, from more than 30% of days on injectable therapies to just 6.2% on stable Palsonify dosing.&nbsp;CEO Scott Struthers called the FDA approval a “new era” for patients and the company, marking the first product launch from its pipeline of small-molecule drugs. The company said Palsonify will be available in the U.S. in early October, supported by a patient services program called CrinetiCARE.Paltusotine is also being evaluated for the treatment of carcinoid syndrome in the pivotal Phase 3 CAREFNDR trial, with global enrollment expected throughout 2025.On Stocktwits, retail sentiment for Crinetics was ‘extremely bullish’ amid a 410% surge in 24-hour message volume, placing it among the top three trending equities on the platform.&nbsp;Users expressed relief after a discussion clarified that while Crinetics sources some ingredients from Europe and previously India, its final tablets are manufactured in the United States, reducing tariff concerns.<stembedurl>https://stocktwits.com/Market_Luther_Kang/message/630073335</stembedurl>Another user remarked that the overwhelmingly positive news, combined with a temporary trading halt, suggested a significant price increase for Crinetics stock could be expected.<stembedurl>https://stocktwits.com/hobbytrader2/message/630067465</stembedurl>Crinetics Pharmaceuticals’ stock has declined 29.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Crinetics Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Retail Chatter Surges As Crinetics Wins FDA Nod For First Oral Acromegaly Drug — Traders Expect Big Price Move

The company plans to launch in the U.S. in early October, with a European launch expected in 2026.

Equity

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates

CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of -8.85% and -79.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline

CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Retail chatter around Crinetics Pharmaceuticals picked up late Sunday after the company released long-term data for its oral acromegaly drug candidate, Palsonify (paltusotine), showing sustained biochemical control and symptom relief across two Phase 3 studies.At the ENDO 2025 conference, Crinetics shared new data from its ongoing PATHFNDR-1 and PATHFNDR-2 studies, showing that patients who switched from monthly injections to once-daily oral Palsonify were able to keep their insulin-like growth factor 1 (IGF-1) and growth hormone levels steady for nearly two years.&nbsp;Symptom scores, based on the acromegaly symptom diary (ASD), also remained stable. Palsonify was generally well tolerated.In PATHFNDR-2, which studied patients with uncontrolled acromegaly, Palsonify led to sustained reductions in IGF-1 and symptom flares through 84 weeks.&nbsp;Notably, patients who had previously been on placebo experienced meaningful improvements after switching to Palsonify in the open-label extension (OLE).A pooled analysis of symptom scores across both studies showed a significant decrease in day-to-day symptom flares for patients switching from injectables from over 30% of days on somatostatin receptor ligand (SRL) to just 6.2% during stable Palsonify dosing, regardless of baseline control or treatment history.CEO Scott Struthers said the data reinforce Palsonify’s potential as a once-daily, next-generation treatment for acromegaly.&nbsp;Crinetics is also advancing Palsonify in a Phase 3 trial for carcinoid syndrome in patients with neuroendocrine tumors, following promising Phase 2 results in flushing and bowel movement control.In March, the European Medicines Agency (EMA) validated Crinetics' marketing authorization application (MAA) for Palsonify as a long-term maintenance therapy for acromegaly.&nbsp;The EMA had previously granted the drug Orphan Drug Designation in February.&nbsp;On Stocktwits, retail sentiment for Crinetics was ‘bullish’ amid ‘high’ message volume.Crinetics’ stock has declined 38.1% so far in 2025.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trumps-35-tariff-threat-ripples-through-walmart-s-bangladesh-supply-chain-report/ch8B1KwR5Np">Trump’s 35% Tariff Threat Ripples Through Walmart’s Bangladesh Supply Chain: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Crinetics Pharmaceuticals' (CRNX) Palsonify (paltusotine) showed sustained biochemical control and symptom relief across two Phase 3 studies. (Photo credit: Getty Images)

Crinetics Pharma’s Oral Drug Shows Lasting Relief For Acromegaly Patients In Latest Study; Retail Buzz Builds

The company presented new data at ENDO 2025 showing that patients who switched from monthly injections to the daily pill maintained hormone control and saw fewer symptom flare-ups over nearly two years. 

Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?

Ionis Pharmaceuticals (IONS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Futures Drop On DOJ's Google Crackdown, China Plunge

Futures Drop On DOJ's Google Crackdown, China Plunge

 US equity futures are lower on news that the DOJ is considering a breakup of Alphabet's Google search engine, in what would be a...

Strong Future for Crinetics Pharmaceuticals: A Comprehensive Buy Rating Justification

Crinetics Pharmaceuticals (CRNX Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jonathan W...

XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...

Forecasting The Future: 11 Analyst Projections For Crinetics Pharmaceuticals

Latest Ratings for CRNX
 DateFirmActionFromTo Nov 2021JMP SecuritiesInitiates Coverage OnMarket Outperform Nov 2021Evercore ISI GroupInitiates Coverage OnOutperform Nov 2021HC Wainwright...

17 Analysts Have This To Say About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

CRNX
Crinetics Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CRNX News

CRNX Crinetics Pharmaceuticals Inc